KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $8.9 million.

  • Castle Biosciences' Other Accumulated Expenses rose 1012.64% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 1012.64%. This contributed to the annual value of $8.0 million for FY2024, which is 923.88% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Other Accumulated Expenses is $8.9 million, which was up 1012.64% from $8.2 million recorded in Q2 2025.
  • Castle Biosciences' Other Accumulated Expenses' 5-year high stood at $8.9 million during Q3 2025, with a 5-year trough of $2.0 million in Q1 2021.
  • Over the past 5 years, Castle Biosciences' median Other Accumulated Expenses value was $6.7 million (recorded in 2024), while the average stood at $6.3 million.
  • In the last 5 years, Castle Biosciences' Other Accumulated Expenses skyrocketed by 22384.16% in 2022 and then tumbled by 1050.51% in 2023.
  • Quarter analysis of 5 years shows Castle Biosciences' Other Accumulated Expenses stood at $5.7 million in 2021, then dropped by 7.33% to $5.3 million in 2022, then surged by 39.05% to $7.3 million in 2023, then rose by 9.24% to $8.0 million in 2024, then grew by 11.16% to $8.9 million in 2025.
  • Its Other Accumulated Expenses stands at $8.9 million for Q3 2025, versus $8.2 million for Q2 2025 and $8.4 million for Q1 2025.